In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring Inc (BYSI), with a price target of $41. The company’s shares closed last Monday at $19.14.
Pantginis said:
“Valuation and risks to price target achievement. We maintain our Buy rating and $41 price target. All of our current valuation is based on the opportunity for Plinabulin with 84% contribution coming from neutropenia and the remainder for NSCLC (higher risk indication). Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, Plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.7% and a 35.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Beyondspring Inc has an analyst consensus of Moderate Buy, with a price target consensus of $41.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.86 and a one-year low of $13.06. Currently, Beyondspring Inc has an average volume of 68.31K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.